Wed, Nov 13, 2024
Volume 11, Issue 3 (May-Jun 2017)
mljgoums 2017, 11(3): 30-34 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Rahimi Z, Salehi M, Dousti A. CCL2 Polymorphism in Drug-Resistant and Drug-Responsive Patients with Epilepsy in Isfahan, Iran. mljgoums 2017; 11 (3) :30-34
URL: http://mlj.goums.ac.ir/article-1-1005-en.html
URL: http://mlj.goums.ac.ir/article-1-1005-en.html
1- Department of Biology, Faculty of Science, Islamic Azad University, Shahrekord, Iran , zahrarahimi700@yahoo.com
2- Department of Human Genetics, School of Medicine, University of Isfahan, Isfahan, Iran
3- Department of Biology, Faculty of Science, Islamic Azad University of Shahrekord, Iran
2- Department of Human Genetics, School of Medicine, University of Isfahan, Isfahan, Iran
3- Department of Biology, Faculty of Science, Islamic Azad University of Shahrekord, Iran
Abstract: (8811 Views)
ABSTRACT
Background and objective: Approximately 50 million people worldwide (1% of the world's population) suffer from epilepsy. Among 700 thousand people with epilepsy in Iran, 20% have refractory epilepsy. Accumulation of leukocytes in patients' brain parenchyma is thought to be related to different types of epilepsy. Recent clinical observations suggest that therapeutic strategies that interfere with leukocytes or cause them to migrate may have therapeutic efficacy in epilepsy. The aim of this study was to identify treatment-resistant patients, and investigate the association between polymorphism rs1024611 in CCL2 gene and drug resistance in patients with epilepsy in Isfahan, Iran.
Methods: Blood samples were taken from 50 patients with intractable epilepsy (case group) and 50 drug-responsive patients with epilepsy (control group). Genomic DNA was extracted from peripheral blood by salting out method. Specific primers were designed by Oligo 7 software to investigate polymorphism rs1024611 using PCR-RFLP. The preliminary results for a number of samples were confirmed by sequencing.
Results: The results of this study showed that there was a significant relationship between intractable epilepsy and presence of C allele.
Conclusion: Similar to previous study, we found a significant association between CCL2 gene polymorphism and drug-resistant epilepsy.
Keywords: Epilepsy, Drug Resistance, Polymorphism, CCL2.
Background and objective: Approximately 50 million people worldwide (1% of the world's population) suffer from epilepsy. Among 700 thousand people with epilepsy in Iran, 20% have refractory epilepsy. Accumulation of leukocytes in patients' brain parenchyma is thought to be related to different types of epilepsy. Recent clinical observations suggest that therapeutic strategies that interfere with leukocytes or cause them to migrate may have therapeutic efficacy in epilepsy. The aim of this study was to identify treatment-resistant patients, and investigate the association between polymorphism rs1024611 in CCL2 gene and drug resistance in patients with epilepsy in Isfahan, Iran.
Methods: Blood samples were taken from 50 patients with intractable epilepsy (case group) and 50 drug-responsive patients with epilepsy (control group). Genomic DNA was extracted from peripheral blood by salting out method. Specific primers were designed by Oligo 7 software to investigate polymorphism rs1024611 using PCR-RFLP. The preliminary results for a number of samples were confirmed by sequencing.
Results: The results of this study showed that there was a significant relationship between intractable epilepsy and presence of C allele.
Conclusion: Similar to previous study, we found a significant association between CCL2 gene polymorphism and drug-resistant epilepsy.
Keywords: Epilepsy, Drug Resistance, Polymorphism, CCL2.
Research Article: Original Paper |
Received: 2017/11/7 | Accepted: 2017/11/7 | Published: 2017/11/7 | ePublished: 2017/11/7
Received: 2017/11/7 | Accepted: 2017/11/7 | Published: 2017/11/7 | ePublished: 2017/11/7
References
1. World Health Organization. www.who.int//mental _health /resources / epilepsy
2. Walker L, Sills GJ. Inflammation and epilepsy: the foundations for a new therapeutic approach in epilepsy? Epilepsy Curr. 2012; 12(1):8-12. doi: 10.5698/1535-7511-12.1.8. [DOI:10.5698/1535-7511-12.1.8]
3. Vezzani A, French J, Bartfai T, Baram TZ. The role of inflammation in epilepsy. Nat Rev Neurol. 2011; 7(1): 31-40. [DOI:10.1038/nrneurol.2010.178]
4. Li Y, He X, Liu Z, Yue X, Zhao P, Hu J, et al. The association between CCL2 polymorphisms and drug-resistant epilepsy in Chinese children. Epileptic Disord. 2013; 15(3): 272-7. doi: 10.1684/epd.2013.0603.
5. Foresti ML, Arisi GM, Katki K, Monta-ez A, Sanchez RM, Shapiro LA. 2009 Chemokine CCL2 and its receptor CCR2 are increased in the hippocampus following pilocarpine-induced status epilepticus. J Neuroinflammation.; 6:40.1328-36.
6. Abbas A, Lichtman AH, Pillai Sh. Cellular and molecular immunology. 7th ed. 2012.
7. Micheva KD, Busse B, Weiler NC, O'Rourke N, Smith SJ. Single-synapse analysis of a diverse synapse population: proteomic imaging methods and markers. Neuron. 2010; 68(4): 639-53. [DOI:10.1016/j.neuron.2010.09.024]
8. Miller BC, Olson TD. Sexual attitudes and behavior of high school students in relation to background and contextual factors. J Sex Res. 1988; 24(1): 194-200. [DOI:10.1080/00224498809551411]
9. Fernandez EJ, Lolis E. Structure, function, and inhibition of chemokines. Annu Rev Pharmacol Toxicol. 2002; 42: 469-99. DOI:10.1146/annurev.pharmtox.42.091901.115838. [DOI:10.1146/annurev.pharmtox.42.091901.115838]
10. O'Donovan N, Galvin M, Morgan JG. Physical mapping of the CXC chemokine locus on human chromosome 4. Cytogenet Cell Genet. 1999; 84(1-2): 39-42. DOI:10.1159/000015209. [DOI:10.1159/000015209]
11. Rovin BH, Lu L, Saxena R. A novel polymorphism in the MCP-1 gene regulatory region that influences MCP-1 expression. Biochem Biophys Res Commun. 1999; 259(2): 344-8. DOI:10.1006/bbrc.1999.0796. [DOI:10.1006/bbrc.1999.0796]
12. Marchi N, Granata T, Freri E, Ciusani E, Ragona F, Puvenna V, et al. Efficacy of anti-inflammatory therapy in a model of acute seizures and in a population of pediatric drug resistant epileptics. PLoSOne 2011; 6: e18200. DOI:10.1371/journal.pone.0018200. [DOI:10.1371/journal.pone.0018200]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Enamad
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.